Clinical Trial Update: FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating FH-FOLR1 CAR T-cell therapy in pediatric patients with relapsed or refractory acute myeloid leukemia; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• FH-FOLR1 CAR T-cell therapy (FH-FOLR1 chimeric antigen receptor T cell therapy)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING